Antiatherogenic role of high-density lipoproteins: Insights from genetically engineered-mice

Frontiers in Bioscience

Volumn 11, Issue 2 P.1199-1590, 2006, Pages 1328-1348

  Escola Gil, Joan Carles ^a   Calpe Berdiel, Laura ^a   Palome, Xavier ^a   Ribas, Vicent ^a   Ordonez Llanos, Jordi ^a   Blanco Vaca, Francisco ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Atherosclerosis; Genetically Engineered Mice; High Density Lipoprotein; Lipoprotein Oxidation; Reverse Cholesterol Transport; Vessel

Indexed keywords

EID: 31044446308     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1887     Document Type: Review

References (257)

1. S. Lund-Katz, L. Liu, S.T. Thuahnai & M.C. Phillips: High density lipoprotein structure. Front Biosci 8,d1044-1054 (2003)
2. A. von Eckardstein, J.R. Nofer & G. Assmann: High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 21,13-27 (2001)
3. G.J. Miller & N.E. Miller: Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1,16-19 (1975)
4. D.J. Gordon & B.M. Rifkind: High-density lipoprotein-the clinical implications of recent studies. N Engl J Med 321,1311-1316 (1989)
5. G.K. Hovingh, E. de Groot, W. van der Steeg, S.M. Boekholdt, B.A. Hutten, J.A. Kuivenhoven & J.J. Kastelein: Inherited disorders of HDL metabolism and atherosclerosis. Curr Opin Lipidol 16,139-145 (2005)
6. M. Miller, J. Rhyne, S. Hamlette, J. Birnbaum & A. Rodriguez: Genetics of HDL regulation in humans. Curr Opin Lipidol 14,273-279 (2003)
7. E.M. Rubin, R.M. Krauss, E.A. Spangler, J.G. Verstuyft & S.M. Clift: Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 353,265-267 (1991)
8. C. Paszty, N. Maeda, J. Verstuyft & E.M. Rubin: Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 94,899-903 (1994)
9. A.S. Plump, C.J. Scott & J.L. Breslow: Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A 91,9607-9611 (1994)
10. J.J. Badimon, L. Badimon & V. Fuster: Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 85,1234-1241 (1990)
11. A. Miyazaki, S. Sakuma, W. Morikawa, T. Takiue, F. Miake, T. Terano, M. Sakai, H. Hakamata, Y. Sakamoto, M. Natio & et al.: Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 15,1882-1888 (1995)
12. A.C. Liu, R.M. Lawn, J.G. Verstuyft & E.M. Rubin: Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice. J Lipid Res 35,2263-2267 (1994)
13. O. Stein & Y. Stein: Lipid transfer proteins (LTP) and atherosclerosis. Atherosclerosis 178,217-230 (2005)
14. R. Williamson, D. Lee, J. Hagaman & N. Maeda: Marked reduction of high density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I. Proc Natl Acad Sci U S A 89,7134-7138 (1992)
15. H. Li, R.L. Reddick & N. Maeda: Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice. Arterioscler Thromb 13,1814-1821 (1993)
16. X. Wang & B. Paigen: Genome-wide search for new genes controlling plasma lipid concentrations in mice and humans. Curr Opin Lipidol 16,127-137 (2005)
17. J.R. Nofer, B. Kehrel, M. Fobker, B. Levkau, G. Assmann & A. von Eckardstein: HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 161,1-16 (2002)
18. G. Assmann & A.M. Gotto, Jr.: HDL cholesterol and protective factors in atherosclerosis. Circulation 109,III8-14 (2004)
19. D.J. Rader: Regulation of reverse cholesterol transport and clinical implications. Am J Cordial 92,42J-49J (2003)
20. P. Linsel-Nitschke & A.R. Tall: HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 4,193-205 (2005)
21. J.F. Oram & S. Yokoyama: Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J Lipid Res 37,2473-2491 (1996)
22. G.H. Rothblat, M. de la Llera-Moya, V. Atger, G. Kellner-Weibel, D.L. Williams & M.C. Phillips: Cell cholesterol efflux: integration of old and new observations provides new insights. J Lipid Res 40,781-796 (1999)
23. Y. Osono, L.A. Woollett, K.R. Marotti, G.W. Melchior & J.M. Dietschy: Centripetal cholesterol flux from extrahepatic organs to the liver is independent of the concentration of high density lipoprotein-cholesterol in plasma. Proc Natl Acad Sci U S A 93,4114-4119 (1996)
24. K. Alam, R.S. Meidell & D.K. Spady: Effect of up-regulating individual steps in the reverse cholesterol transport pathway on reverse cholesterol transport in normolipidemic mice. J Biol Chem 276,15641-15649 (2001)
25. C.D. Jolley, L.A. Woollett, S.D. Turley & J.M. Dietschy: Centripetal cholesterol flux to the liver is dictated by events in the peripheral organs and not by the plasma high density lipoprotein or apolipoprotein A-I concentration. J Lipid Res 39,2143-2149 (1998)
26. B. Angelin, P. Parini & M. Eriksson: Reverse cholesterol transport in man: promotion of fecal steroid excretion by infusion of reconstituted HDL. Atheroscler Suppl 3,23-30 (2002)
27. O. Stein & Y. Stein: Atheroprotective mechanisms of HDL. Atherosclerosis 144,285-301 (1999)
28. A.R. Tall, N. Wang & P. Mucksavage: Is it time to modify the reverse cholesterol transport model? J Clin Invest 108,1273-1275 (2001)
29. Y. Zhang, I. Zanotti, M.P. Reilly, J.M. Glick, G.H. Rothblat & D.J. Rader: Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation 108,661-663 (2003)
30. J.K. Kruit, T. Plosch, R. Havinga, R. Boverhof, P.H. Groot, A.K. Groen & F. Kuipers: Increased fecal neutral sterol loss upon liver X receptor activation is independent of biliary sterol secretion in mice. Gastroenterology 128,147-156 (2005)
31. P. Benoit, F. Emmanuel, J.M. Caillaud, L. Bassinet, G. Castro, P. Gallix, J.C. Fruchart, D. Branellec, P. Denefle & N. Duverger: Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models. Circulation 99,105-110 (1999)
32. R.K. Tangirala, K. Tsukamoto, S.H. Chun, D. Usher, E. Pure & D.J. Rader: Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 100,1816-1822 (1999)
33. G. Chiesa, C. Parolini, M. Canavesi, N. Colombo, C.R. Sirtori, R. Fumagalli, G. Franceschini & F. Bernini: Human apolipoproteins A-I and A-II in cell cholesterol efflux: studies with transgenic mice. Arterioscler Thromb Vasc Biol 18,1417-1423 (1998)
34. O. Stein, Y. Dabach, G. Hollander, M. Ben-Naim, G. Halperin & Y. Stein: High levels of human apolipoprotein A-I and high density lipoproteins in transgenic mice do not enhance efflux of cholesterol from a depot of injected lipoproteins. Relevance to regression of atherosclerosis? Atherosclerosis 144,367-374 (1999)
35. M. Navab, G.M. Anantharamaiah, S. Hama, D.W. Garber, M. Chaddha, G. Hough, R. Lallone & A.M. Fogelman: Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 105,290-292 (2002)
36. D.W. Garber, G. Datta, M. Chaddha, M.N. Palgunachari, S.Y. Hama, M. Navab, A.M. Fogelman, J.P. Segrest & G.M. Anantharamaiah: A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res 42,545-552 (2001)
37. X. Li, K.Y. Chyu, J.R. Neto, J. Yano, N. Nathwani, C. Ferreira, P.C. Dimayuga, B. Cercek, S. Kaul & P.K. Shah: Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 110,1701-1705 (2004)
38. M. Navab, G.M. Anantharamaiah, S.T. Reddy, S. Hama, G. Hough, V.R. Grijalva, A.C. Wagner, J.S. Frank, G. Datta, D. Garber & A.M. Fogelman: Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 109,3215-3220 (2004)
39. N. Wang, W. Chen, P. Linsel-Nitschke, L.O. Martinez, B. Agerholm-Larsen, D.L. Silver & A.R. Tall: A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I. J Clin Invest 111,99-107 (2003)
40. E. Voyiaziakis, I.J. Goldberg, A.S. Plump, E.M. Rubin, J.L. Breslow & L.S. Huang: ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice. J Lipid Res 39,313-321 (1998)
41. R.E. Moore, M.A. Kawashiri, K. Kitajima, A. Secreto, J.S. Millar, D. Pratico & D.J. Rader. Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking the LDL receptor. Arterioscler Thromb Vasc Biol 23,1914-1920 (2003)
42. O. Stein, Y. Dabach, G. Hollander, M. Ben-Naim, G. Halperin, J.L. Breslow & Y. Stein: Delayed loss of cholesterol from a localized lipoprotein depot in apolipoprotein A-I-deficient mice. Proc Natl Acad Sci U S A 94,9820-9824 (1997)
43. C.D. Jolley, J.M. Dietschy & S.D. Turley: Induction of bile acid synthesis by cholesterol and cholestyramine feeding is unimpaired in mice deficient in apolipoprotein AI. Hepatology 32,1309-1316 (2000)
44. C.R. Sirtori, L. Calabresi, G. Franceschini, D. Baldassarre, M. Amato, J. Johansson, M. Salvetti, C. Monteduro, R. Zulli, M.L. Muiesan & E. Agabiti-Rosei: Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation 103,1949-1954 (2001)
45. K.H. Weisgraber, T.P. Bersot, R.W. Mahley, G. Franceschini & C.R. Sirtori: A-Imilano apoprotein. Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins. J Clin Invest 66,901-907 (1980)
46. G. Franceschini, L. Calabresi, G. Chiesa, C. Parolini, C.R. Sirtori, M. Canavesi & F. Bernini: Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice. Arterioscler Thromb Vasc Biol 19,1257-1262 (1999)
47. P.K. Shah, J. Nilsson, S. Kaul, M.C. Fishbein, H. Ageland, A. Hamsten, J. Johansson, F. Karpe & B. Cercek: Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation 97,780-785 (1998)
48. P.K. Shah, J. Yano, O. Reyes, K.Y. Chyu, S. Kaul, C.L. Bisgaier, S. Drake & B. Cercek: High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization. Circulation 103,3047-3050 (2001)
49. S. Kaul, B. Coin, A. Hedayiti, J. Yano, B. Cercek, K.Y. Chyu & P.K. Shah: Rapid reversal of endothelial dysfunction in hypercholesterolemic apolipoprotein E-null mice by recombinant apolipoprotein A-I(Milano)- phospholipid complex. J Am Coll Cordial 44,1311-1319 (2004)
50. S.E. Nissen, T. Tsunoda, E.M. Tuzcu, P. Schoenhagen, C.J. Cooper, M. Yasin, G.M. Eaton, M.A. Lauer, W.S. Sheldon, C.L. Grines, S. Halpern, T. Crowe, J.C. Blankenship & R. Kerensky: Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. Jama 290,2292-2300 (2003)
51. C.H. Warden, C.C. Hedrick, J.H. Qiao, L.W. Castellani & A.J. Lusis: Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science 261,469-472 (1993)
52. J.C. Escola-Gil, A. Marzal-Casacuberta, J. Julve-Gil, B.Y. Ishida, J. Ordonez-Llanos, L. Chan, F. Gonzalez-Sastre & F. Blanco-Vaca: Human apolipoprotein A-II is a pro-atherogenic molecule when it is expressed in transgenic mice at a level similar to that in humans: evidence of a potentially relevant species-specific interaction with diet. J Lipid Res 39,457-462 (1998)
53. J.C. Escola-Gil, J. Julve, A. Marzal-Casacuberta, J. Ordonez-Llanos, F. Gonzalez-Sastre & F. Blanco-Vaca: ApoA-II expression in CETP transgenic mice increases VLDL production and impairs VLDL clearance. J Lipid Res 42,241-248 (2001)
54. V. Ribas, J.L. Sanchez-Quesada, R. Anton, M. Camacho, J. Julve, J.C. Escola-Gil, L. Vila, J. Ordonez-Llanos & F. Blanco-Vaca: Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential. Circ Res 95,789-797 (2004)
55. J.C. Escola-Gil, J. Julve, A. Marzal-Casacuberta, J. Ordonez-Llanos, F. Gonzalez-Sastre & F. Blanco-Vaca: Expression of human apolipoprotein A-II in apolipoprotein E-deficient mice induces features of familial combined hyperlipidemia. J Lipid Res 41,1328-1338 (2000)
56. F. Blanco-Vaca, J.C. Escola-Gil, J.M. Martin-Campos & J. Julve: Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein. J Lipid Res 42,1727-1739 (2001)
57. A. Tailleux, P. Duriez, J.C. Fruchart & V. Clavey: Apolipoprotein A-II, HDL metabolism and atherosclerosis. Atherosclerosis 164,1-13 (2002)
58. A.D. Kalopissis, D. Pastier & J. Chambaz: Apolipoprotein A-II: beyond genetic associations with lipid disorders and insulin resistance. Curr Opin Lipidol 14,165-172 (2003)
59. J.M. Martin-Campos, J.C. Escola-Gil, V. Ribas & F. Blanco-Vaca: Apolipoprotein A-II, genetic variation on chromosome Iq21-q24, and disease susceptibility. Curr Opin Lipidol 15,247-253 (2004)
60. F. Rinninger, M. Brundert, R.M. Budzinski, J.C. Fruchart, H. Greten & G.R. Castro: Scavenger receptor BI (SR-BI) mediates a higher selective cholesteryl ester uptake from LpA-I compared with LpA-I:A-II lipoprotein particles. Atherosclerosis 166,31-40 (2003)
61. M.C. de Beer, D.M. Durbin, L. Cai, N. Mirocha, A. Jonas, N.R. Webb, F.C. de Beer & D.R. van Der Westhuyzen: Apolipoprotein A-II modulates the binding and selective lipid uptake of reconstituted high density lipoprotein by scavenger receptor BI. J Biol Chem 276,15832-15839 (2001)
62. A. Pilon, O. Briand, S. Lestavel, C. Copin, Z. Majd, J.C. Fruchart, G. Castro & V. Clavey: Apolipoprotein AII enrichment of HDL enhances their affinity for class B type I scavenger receptor but inhibits specific cholesteryl ester uptake. Arterioscler Thromb Vasc Biol 20,1074-1081 (2000)
63. J. Julve, J.C. Escola-Gil, V. Ribas, F. Gonzalez-Sastre, J. Ordonez-Llanos, J.L. Sanchez-Quesada & F. Blanco-Vaca: Mechanisms of HDL deficiency in mice overexpressing human apoA-II. J Lipid Res 43,1734-1742 (2002)
64. M.C. de Beer, L.W. Castellani, L. Cai, A.J. Stromberg, F.C. de Beer & D.R. van der Westhuyzen: ApoA-II modulates the association of HDL with class B scavenger receptors SR-BI and CD36. J Lipid Res 45,706-715 (2004)
65. N. Fournier, A. Cogny, V. Atger, D. Pastier, D. Goudouneche, A. Nicoletti, N. Moatti, J. Chambaz, J.L. Paul & A.D. Kalopissis: Opposite effects of plasma from human apolipoprotein A-II transgenic mice on cholesterol efflux from J774 macrophages and Fu5AH hepatoma cells. Arterioscler Thromb Vasc Biol 22,638-643 (2002)
66. J. Julve-Gil, E. Ruiz-Perez, R.P. Casaroli-Marano, A. Marzal-Casacuberta, J.C. Escola-Gil, F. Gonzalez-Sastre & F. Blanco-Vaca: Free cholesterol deposition in the cornea of human apolipoprotein A-II transgenic mice with functional lecithin: cholesterol acyltransferase deficiency. Metabolism 48,415-421 (1999)
67. A. Tailleux, M. Bouly, G. Luc, G. Castro, J.M. Caillaud, N. Hennuyer, P. Poulain, J.C. Fruchart, N. Duverger & C. Fievet: Decreased susceptibility to diet-induced atherosclerosis in human apolipoprotein A-II transgenic mice. Arterioscler Thromb Vasc Biol 20,2453-2458 (2000)
68. L.W. Castellani, M. Navab, B.J. Van Lenten, C.C. Hedrick, S.Y. Hama, A.M. Goto, A.M. Fogelman & A.J. Lusis: Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles. J Clin Invest 100,464-474 (1997)
69. N. Rotllan, V. Ribas, L. Calpe-Berdiel, J.M. Martin-Campos, F. Blanco-Vaca & J.C. Escola-Gil: Overexpression of human apolipoprotein A-II in transgenic mice does not impair macrophage-specific reverse cholesterol transport in vivo. Arterioscler Thromb Vasc Biol 25,e128-132 (2005)
70. M. Brundert, J. Heeren, H. Greten & F. Rinninger: Hepatic lipase mediates an increase in selective uptake of HDL-associated cholesteryl esters by cells in culture independent from SR-BI. J Lipid Res 44,1020-1032 (2003)
71. G. Vassiliou & R. McPherson: A novel efflux-recapture process underlies the mechanism of high-density lipoprotein cholesteryl ester-selective uptake mediated by the low-density lipoprotein receptor-related protein. Arterioscler Thromb Vasc Biol 24,1669-1675 (2004)
72. N.A. Elshourbagy, D.W. Walker, Y.K. Paik, M.S. Boguski, M. Freeman, J.I. Gordon & J.M. Taylor: Structure and expression of the human apolipoprotein A-IV gene. J Biol Chem 262,7973-7981 (1987)
73. A. Steinmetz & G. Utermann: Activation of lecithin: cholesterol acyltransferase by human apolipoprotein A-IV. J Biol Chem 260,2258-2264 (1985)
74. N. Fournier, V. Atger, J.L. Paul, M. Sturm, N. Duverger, G.H. Rothblat & N. Moatti: Human ApoA-IV overexpression in transgenic mice induces cAMP-stimulated cholesterol efflux from J774 macrophages to whole serum. Arterioscler Thromb Vasc Biol 20,1283-1292 (2000)
75. R.D. Cohen, L.W. Castellani, J.H. Qiao, B.J. Van Lenten, A.J. Lusis & K. Reue: Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV. J Clin Invest 99,1906-1916 (1997)
76. N. Duverger, G. Tremp, J.M. Caillaud, F. Emmanuel, G. Castro, J.C. Fruchart, A. Steinmetz & P. Denefle: Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science 273,966-968 (1996)
77. Y. Stein, O. Stein, N. Duverger, G. Halperin, Y. Dabach, G. Hollander & M. Ben-Naim: Clearance of cationized LDL cholesterol from a muscle depot is not enhanced in human apolipoprotein A-IV transgenic mice. Arterioscler Thromb Vasc Biol 20,179-184 (2000)
78. M.F. Linton, J.B. Atkinson & S. Fazio: Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science 267,1034-1037 (1995)
79. W.A. Boisvert, J. Spangenberg & L.K. Curtiss: Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by bone marrow transplantation. J Clin Invest 96,1118-1124 (1995)
80. S. Bellosta, R.W. Mahley, D.A. Sanan, J. Murata, D.L. Newland, J.M. Taylor & R.E. Pitas: Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J Clin Invest 96,2170-2179 (1995)
81. C. Wolfrum, M.N. Poy & M. Stoffel: Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med 11,418-422 (2005)
82. P.G. Frank, A. Pedraza, D.E. Cohen & M.P. Lisanti: Adenovirus-mediated expression of caveolin-1 in mouse liver increases plasma high-density lipoprotein levels. Biochemistry 40,10892-10900 (2001)
83. A. Brooks-Wilson, M. Marcil, S.M. Clee, L.H. Zhang, K. Roomp, M. van Dam, L. Yu, C. Brewer, J.A. Collins, H.O. Molhuizen, O. Loubser, B.F. Ouelette, K. Fichter, K.J. Ashbourne-Excoffon, C.W. Sensen, S. Scherer, S. Mott, M. Denis, D. Martindale, J. Frohlich, K. Morgan, B. Koop, S. Pimstone, J.J. Kastelein, M.R. Hayden & et al.: Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 22,336-345 (1999)
84. M. Bodzioch, E. Orso, J. Klucken, T. Langmann, A. Bottcher, W. Diederich, W. Drobnik, S. Barlage, C. Buchler, M. Porsch-Ozcurumez, W.E. Kaminski, H. W. Hahmann, K. Oette, G. Rothe, C. Aslanidis, K.J. Lackner & G. Schmitz: The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 22,347-351 (1999)
85. S. Rust, M. Rosier, H. Funke, J. Real, Z. Amoura, J.C. Piette, J.F. Deleuze, H.B. Brewer, N. Duverger, P. Denefle & G. Assmann: Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 22,352-355 (1999)
86. B.L. Vaisman, G. Lambert, M. Amar, C. Joyce, T. Ito, R.D. Shamburek, W.J. Cain, J. Fruchart-Najib, E.D. Neufeld, A.T. Remaley, H.B. Brewer, Jr. & S. Santamarina-Fojo: ABCAl overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. J Clin Invest 108,303-309 (2001)
87. F. Basso, L. Freeman, C.L. Knapper, A. Remaley, J. Stonik, E.B. Neufeld, T. Tansey, M.J. Amar, J. Fruchart-Najib, N. Duverger, S. Santamarina-Fojo & H.B. Brewer, Jr.: Role of the hepatic ABCA1 transporter in modulating intrahepatic cholesterol and plasma HDL cholesterol concentrations. J Lipid Res 44,296-302 (2003)
88. C.L. Wellington, L.R. Brunham, S. Zhou, R.R. Singaraja, H. Visscher, A. Gelfer, C. Ross, E. James, G. Liu, M.T. Huber, Y.Z. Yang, R.J. Parks, A. Groen, J. Fruchart-Najib & M.R. Hayden: Alterations of plasma lipids in mice via adenoviral-mediated hepatic overexpression of human ABCA1. J Lipid Res 44,1470-1480 (2003)
89. S. Murthy, E. Born, S.N. Mathur & F.J. Field: LXR/RXR activation enhances basolateral efflux of cholesterol in CaCo-2 cells. J Lipid Res 43,1054-1064 (2002)
90. J.D. Mulligan, M.T. Flowers, A. Tebon, J.J. Bitgood, C. Wellington, M.R. Hayden & A.D. Attie: ABCA1 is essential for efficient basolateral cholesterol efflux during the absorption of dietary cholesterol in chickens. J Biol Chem 278,13356-13366 (2003)
91. C.W. Joyce, M.J. Amar, G. Lambert, B.L. Vaisman, B. Paigen, J. Najib-Fruchart, R.F. Hoyt, Jr., E.D. Neufeld, A.T. Remaley, D.S. Fredrickson, H.B. Brewer, Jr. & S. Santamarina-Fojo: The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc Natl Acad Sci U S A 99,407-412 (2002)
92. A.K. Groen, V.W. Bloks, R.H. Bandsma, R. Ottenhoff, G. Chimini & F. Kuipers: Hepatobiliary cholesterol transport is not impaired in Abca1-null mice lacking HDL. J Clin Invest 108,843-850 (2001)
93. T. Plosch, T. Kok, V.W. Bloks, M.J. Smit, R. Havinga, G. Chimini, A.K. Groen & F. Kuipers: Increased hepatobiliary and fecal cholesterol excretion upon activation of the liver X receptor is independent of ABCA1. J Biol Chem 277,33870-33877 (2002)
94. J. McNeish, R.J. Aiello, D. Guyot, T. Turi, C. Gabel, C. Aldinger, K.L. Hoppe, M.L. Roach, L.J. Royer, J. de Wet, C. Broccardo, G. Chimini & O.L. Francone: High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc Natl Acad Sci U S A 97,4245-4250 (2000)
95. R.J. Aiello, D. Brees, P.A. Bourassa, L. Royer, S. Lindsey, T. Coskran, M. Haghpassand & O.L. Francone: Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arterioscler Thromb Vasc Biol 22,630-637 (2002)
96. J.M. Timmins, J.Y. Lee, E. Boudyguina, K.D. Kluckman, L.R. Brunham, A. Mulya, A.K. Gebre, J.M. Coutinho, P.L. Colvin, T.L. Smith, M.R. Hayden, N. Maeda & J.S. Parks: Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest 115,1333-1342 (2005)
97. J. Klucken, C. Buchler, E. Orso, W.E. Kaminski, M. Porsch-Ozcurumez, G. Liebisch, M. Kapinsky, W. Diederich, W. Drobnik, M. Dean, R. Allikmets & G. Schmitz: ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport Proc Natl Acad Sci U S A 97,817-822 (2000)
98. B.A. Laffitte, J.J. Repa, S.B. Joseph, D.C. Wilpitz, H.R. Kast, D.J. Mangelsdorf & P. Tontonoz: LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci U S A 98,507-512 (2001)
99. G. Schmitz, T. Langmann & S. Heimerl: Role of ABCG1 and other ABCG family members in lipid metabolism. J Lipid Res 42,1513-1520 (2001)
100. N. Wang, D. Lan, W. Chen, F. Matsuura & A.R. Tall: ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci U S A 101,9774-9779 (2004)
101. B.G. Kennedy MA, Nakamura K, Baldán A, Tarr P, Fishbein M, Frank J, Francone OL, Edwards A: ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metabolism 1,121-131 (2005)
102. T. Ito: Physiological function of ABCG1. Drug News Perspect 16,490-492 (2003)
103. S. Oldfield, C. Lowry, J. Ruddick & S. Lightman: ABCG4: a novel human white family ABC-transporter expressed in the brain and eye. Biochim Biophys Acta 1591,175-179 (2002)
104. I.J. Goldberg: Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 37,693-707 (1996)
105. S.M. Clee, H. Zhang, N. Bissada, L. Miao, E. Ehrenborg, P. Benlian, G.X. Shen, A. Angel, R.C. LeBoeuf & M.R. Hayden: Relationship between lipoprotein lipase and high density lipoprotein cholesterol in mice: modulation by cholesteryl ester transfer protein and dietary status. J Lipid Res 38,2079-2089 (1997)
106. T. Coleman, R.L. Seip, J.M. Gimble, D. Lee, N. Maeda & C.F. Semenkovich: COOH-terminal disruption of lipoprotein lipase in mice is lethal in homozygotes, but heterozygotes have elevated triglycerides and impaired enzyme activity. J Biol Chem 270,12518-12525 (1995)
107. P.M. Weinstock, C.L. Bisgaier, K. Aalto-Setala, H. Radner, R. Ramakrishnan, S. Levak-Frank, A.D. Essenburg, R. Zechner & J.L. Breslow: Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes. J Clin Invest 96,2555-2568 (1995)
108. J.G. Strauss, S. Frank, D. Kratky, G. Hammerle, A. Hrzenjak, G. Knipping, A. von Eckardstein, G.M. Kostner & R. Zechner: Adenovirus-mediated rescue of lipoprotein lipase-deficient mice. Lipolysis of triglyceride-rich lipoproteins is essential for high density lipoprotein maturation in mice. J Biol Chem 276,36083-36090 (2001)
109. U. Panzenboeck, A. Wintersberger, S. Levak-Frank, R. Zimmermann, R. Zechner, G.M. Kostner, E. Malle & W. Sattler: Implications of endogenous and exogenous lipoprotein lipase for the selective uptake of HDL3-associated cholesteryl esters by mouse peritoneal macrophages. J Lipid Res 38,239-253 (1997)
110. F. Rinninger, M. Brundert, I. Brosch, N. Donarski, R.M. Budzinski & H. Greten: Lipoprotein lipase mediates an increase in selective uptake of HDL-associated cholesteryl esters by cells in culture independent of scavenger receptor BI. J Lipid Res 42,1740-1751 (2001)
111. F. Rinninger, T. Kaiser, W.A. Mann, N. Meyer, H. Greten & U. Beisiegel: Lipoprotein lipase mediates an increase in the selective uptake of high density lipoprotein-associated cholesteryl esters by hepatic cells in culture. J Lipid Res 39,1335-1348 (1998)
112. S. Levak-Frank, P.H. Weinstock, T. Hayek, R. Verdery, W. Hofmann, R. Ramakrishnan, W. Sattler, J.L. Breslow & R. Zechner: Induced mutant mice expressing lipoprotein lipase exclusively in muscle have subnormal triglycerides yet reduced high density lipoprotein cholesterol levels in plasma. J Biol Chem 272,17182-17190 (1997)
113. V.R. Babaev, S. Fazio, L.A. Gleaves, K.J. Carter, C.F. Semenkovich & M.F. Linton: Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in vivo. J Clin Invest 103,1697-1705 (1999)
114. V.R. Babaev, M.B. Patel, C.F. Semenkovich, S. Fazio & M.F. Linton: Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice. J Biol Chem 275,26293-26299 (2000)
115. G. Lambert, M.J. Amar, P. Martin, J. Fruchart-Najib, B. Foger, R.D. Shamburek, H.B. Brewer, Jr. & S. Santamarina-Fojo: Hepatic lipase deficiency decreases the selective uptake of HDL-cholesteryl esters in vivo. J Lipid Res 41,667-672 (2000)
116. S.J. Busch, R.L. Bamhart, G.A. Martin, M.C. Fitzgerald, M.T. Yates, S.J. Mao, C.E. Thomas & R.L. Jackson: Human hepatic triglyceride lipase expression reduces high density lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice. J Biol Chem 269,16376-16382 (1994)
117. H.L. Dichek, W. Brecht, J. Fan, Z.S. Ji, S.P. McCormick, H. Akeefe, L. Conzo, D.A. Sanan, K.H. Weisgraber, S.G. Young, J.M. Taylor & R.W. Mahley: Overexpression of hepatic lipase in transgenic mice decreases apolipoprotein B-containing and high density lipoproteins. Evidence that hepatic lipase acts as a ligand for lipoprotein uptake. J Biol Chem 273,1896-1903 (1998)
118. K.A. Dugi, M.J. Amar, C.C. Haudenschild, R.D. Shamburek, A. Bensadoun, R.F. Hoyt, Jr., J. Fruchart-Najib, Z. Madj, H.B. Brewer, Jr. & S. Santamarina-Fojo: In vivo evidence for both lipolytic and nonlipolytic function of hepatic lipase in the metabolism of HDL. Arterioscler Thromb Vasc Biol 20,793-800 (2000)
119. Z. Nong, H. Gonzalez-Navarro, M. Amar, L. Freeman, C. Knapper, E.B. Neufeld, B.J. Paigen, R.F. Hoyt, J. Fruchart-Najib & S. Santamarina-Fojo: Hepatic lipase expression in macrophages contributes to atherosclerosis in apoE-deficient and LCAT-transgenic mice. J Clin Invest 112,367-378 (2003)
120. H. Mezdour, R. Jones, C. Dengremont, G. Castro & N. Maeda: Hepatic lipase deficiency increases plasma cholesterol but reduces susceptibility to atherosclerosis in apolipoprotein E-deficient mice. J Biol Chem 272,13570-13575 (1997)
121. L. Amigo, P. Mardones, C. Ferrada, S. Zanlungo, F. Nervi, J.F. Miquel & A. Rigotti: Biliary lipid secretion, bile acid metabolism, and gallstone formation are not impaired in hepatic lipase-deficient mice. Hepatology 38,726-734 (2003)
122. M.G. McCoy, G.S. Sun, D. Marchadier, C. Maugeais, J.M. Glick & D.J. Rader Characterization of the lipolytic activity of endothelial lipase. J Lipid Res 43,921-929 (2002)
123. M. Jaye & J. Krawiec: Endothelial lipase and HDL metabolism. Curr Opin Lipidol 15,183-189 (2004)
124. M. Jaye, K.J. Lynch, J. Krawiec, D. Marchadier, C. Maugeais, K. Doan, V. South, D. Amin, M. Perrone & D.J. Rader: A novel endothelial-derived lipase that modulates HDL metabolism. Nat Genet 21,424-428 (1999)
125. T. Ishida, S. Choi, R.K. Kundu, K. Hirata, E.M. Rubin, A.D. Cooper & T. Quertermous: Endothelial lipase is a major determinant of HDL level. J Clin Invest 111,347-355 (2003)
126. C. Maugeais, U.J. Tietge, U.C. Broedl, D. Marchadier, W. Cain, M.G. McCoy, S. Lund-Katz, J.M. Glick & D.J. Rader: Dose-dependent acceleration of high-density lipoprotein catabolism by endothelial lipase. Circulation 108,2121-2126 (2003)
127. W. Jin, J.S. Millar, U. Broedl, J.M. Glick & D.J. Rader: Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. J Clin Invest 111,357-362 (2003)
128. K. Ma, M. Cilingiroglu, J.D. Otvos, C.M. Ballantyne, A.J. Marian & L. Chan: Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. Proc Natl Acad Sci U S A 100,2748-2753 (2003)
129. T. Ishida, S.Y. Choi, R.K. Kundu, J. Spin, T. Yamashita, K. Hirata, Y. Kojima, M. Yokoyama, A.D. Cooper & T. Quertermous: Endothelial lipase modulates susceptibility to atherosclerosis in apolipoprotein-E-deficient mice. J Biol Chem 279,45085-45092 (2004)
130. S. Santamarina-Fojo, G. Lambert, J.M. Hoeg & H.B. Brewer, Jr.: Lecithin-cholesterol acyltransferase: role in lipoprotein metabolism, reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol 11,267-275 (2000)
131. A.H. Zhang, S. Gao, J.L. Fan, W. Huang, T.Q. Zhao & G. Liu: Increased plasma HDL cholesterol levels and biliary cholesterol excretion in hamster by LCAT overexpression. FEBS Lett 570,25-29 (2004)
132. A.M. Berard, B. Foger, A. Remaley, R. Shamburek, B.L. Vaisman, G. Talley, B. Paigen, R.F. Hoyt, Jr., S. Marcovina, H.B. Brewer, Jr. & S. Santamarina-Fojo: High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat Med 3,744-749 (1997)
133. A. Mehlum, M. Muri, T.A. Hagve, L.A. Solberg & H. Prydz: Mice overexpressing human lecithin: cholesterol acyltransferase are not protected against diet-induced atherosclerosis. Apmis 105,861-868 (1997)
134. J.W. Furbee, Jr. & J.S. Parks: Transgenic overexpression of human lecithin: cholesterol acyltransferase (LCAT) in mice does not increase aortic cholesterol deposition. Atherosclerosis 165,89-100 (2002)
135. B. Foger, M. Chase, M.J. Amar, B.L. Vaisman, R.D. Shamburek, B. Paigen, J. Fruchart-Najib, J.A. Paiz, C.A. Koch, R.F. Hoyt, H.B. Brewer, Jr. & S. Santamarina-Fojo: Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J Biol Chem 274,36912-36920 (1999)
136. G. Lambert, N. Sakai, B.L. Vaisman, E.B. Neufeld, B. Marteyn, C.C. Chan, B. Paigen, E. Lupia, A. Thomas, L.J. Striker, J. Blanchette-Mackie, G. Csako,
137. J.W. Furbee, Jr., J.K. Sawyer & J.S. Parks: Lecithin:cholesterol acyltransferase deficiency increases atherosclerosis in the low density lipoprotein receptor and apolipoprotein E knockout mice. J Biol Chem 277,3511-3519 (2002)
138. D.S. Ng, G.F. Maguire, J. Wylie, A. Ravandi, W. Xuan, Z. Ahmed, M. Eskandarian, A. Kuksis & P.W. Connelly: Oxidative stress is markedly elevated in lecithin:cholesterol acyltransferase-deficient mice and is paradoxically reversed in the apolipoprotein E knockout background in association with a reduction in atherosclerosis. J Biol Chem 277,11715-11720 (2002)
139. A.R. Tall: Plasma cholesteryl ester transfer protein. J Lipid Res 34,1255-1274 (1993)
140. L.B. Agellon, A. Walsh, T. Hayek, P. Moulin, X.C. Jiang, S.A. Shelanski, J.L. Breslow & A.R. Tall: Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J Biol Chem 266,10796-10801 (1991)
141. K.R. Marotti, C.K. Castle, R.W. Murray, E.F. Rehberg, H.G. Polites & G.W. Melchior. The role of cholesteryl ester transfer protein in primate apolipoprotein A-I metabolism. Insights from studies with transgenic mice. Arterioscler Thromb 12,736-744 (1992)
142. G.W. Melchior, C.K. Castle, R.W. Murray, W.L. Blake, D.M. Dinh & K.R. Marotti: Apolipoprotein A-I metabolism in cholesteryl ester transfer protein transgenic mice. Insights into the mechanisms responsible for low plasma high density lipoprotein levels. J Biol Chem 269,8044-8051 (1994)
143. O.L. Francone, L. Royer & M. Haghpassand: Increased prebeta-HDL levels, cholesterol efflux, and LCAT-mediated esterification in mice expressing the human cholesteryl ester transfer protein (CETP) and human apolipoprotein A-I (apoA-I) transgenes. J Lipid Res 37,1268-1277(1996)
144. X.C. Jiang, L. Masucci-Magoulas, J. Mar, M. Lin, A. Walsh, J.L. Breslow & A. Tall: Down-regulation of mRNA for the low density lipoprotein receptor in transgenic mice containing the gene for human cholesteryl ester transfer protein. Mechanism to explain accumulation of lipoprotein B particles. J Biol Chem 268,27406-27412 (1993)
145. O. Stein, Y. Dabach, G. Hollander, M. Ben-Naim, G. Halperin & Y. Stein: Reverse cholesterol transport in mice expressing simian cholesteryl ester transfer protein. Atherosclerosis 164,73-78 (2002)
146. G.J. de Grooth, A.H. Klerkx, E.S. Shoes, A.F. Stalenhoef, J.J. Kastelein & J.A. Kuivenhoven: A review of CETP and its relation to atherosclerosis. J Lipid Res 45,1967-1974 (2004)
147. K.R. Marotti, C.K. Castle, T.P. Boyle, A.H. Lin, R.W. Murray & G.W. Melchior Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 364,73-75 (1993)
148. T. Hayek, L. Masucci-Magoulas, X. Jiang, A. Walsh, E. Rubin, J.L. Breslow & A.R. Tall: Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest 96,2071-2074 (1995)
149. J.D. Curb, R.D. Abbott, B.L. Rodriguez, K. Masaki, R. Chen, D.S. Sharp & A.R. Tall: A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res 45,948-953 (2004)
150. M.E. Brousseau, E.J. Schaefer, M.L. Wolfe, L.T. Bloedon, A.G. Digenio, R.W. Clark, J.P. Mancuso & D.J. Rader: Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350,1505-1515 (2004)
151. G.J. de Grooth, J.A. Kuivenhoven, A.F. Stalenhoef, J. de Graaf, A.H. Zwinderman, J.L. Posma, A. van Tol & J.J. Kastelein: Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 105,2159-2165 (2002)
152. H. Okamoto, F. Yonemori, K. Wakitani, T. Minowa, K. Maeda & H. Shinkai: A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406,203-207 (2000)
153. A. van Tol: Phospholipid transfer protein. Curr Opin Lipidol 13,135-139 (2002)
154. R. van Haperen, A. van Tol, P. Vermeulen, M. Jauhiainen, T. van Gent, P. van den Berg, S. Ehnholm, F. Grosveld, A. van der Kamp & R. de Crom: Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol 20,1082-1088 (2000)
155. X.C. Jiang, C. Bruce, J. Mar, M. Lin, Y. Ji, O.L. Francone & A.R. Tall: Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest 103,907-914 (1999)
156. X.C. Jiang, S. Qin, C. Qiao, K. Kawano, M. Lin, A. Skold, X. Xiao & A.R. Tall: Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med 7,847-852 (2001)
157. S.M. Post, R. de Crom, R. van Haperen, A. van Tol & H.M. Princen: Increased fecal bile acid excretion in transgenic mice with elevated expression of human phospholipid transfer protein. Arterioscler Thromb Vasc Biol 23,892-897 (2003)
158. B. Foger, S. Santamarina-Fojo, R.D. Shamburek, C.L. Parrot, G.D. Talley & H.B. Brewer, Jr.: Plasma phospholipid transfer protein. Adenovirus-mediated overexpression in mice leads to decreased plasma high density lipoprotein (HDL) and enhanced hepatic uptake of phospholipids and cholesteryl esters from HDL. J Biol Chem 272,27393-27400 (1997)
159. R. van Haperen, A. van Tol, T. van Gent, L. Scheek, P. Visser, A. van der Kamp, F. Grosveld & R. de Crom: Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein. J Biol Chem 277,48938-48943 (2002)
160. J. Lie, R. de Crom, T. van Gent, R. van Haperen, L. Scheek, F. Sadeghi-Niaraki & A. van Tol: Elevation of plasma phospholipid transfer protein increases the risk of atherosclerosis despite lower apolipoprotein B-containing lipoproteins. J Lipid Res 45,805-811 (2004)
161. S. Acton, A. Rigotti, K.T. Landschulz, S. Xu, H.H. Hobbs & M. Krieger: Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271,518-520 (1996)
162. C. Glass, R.C. Pittman, D.B. Weinstein & D. Steinberg: Dissociation of tissue uptake of cholesterol ester from that of apoprotein A-I of rat plasma high density lipoprotein: selective delivery of cholesterol ester to liver, adrenal, and gonad. Proc Natl Acad Sci U S A 80,5435-5439 (1983)
163. B.L. Trigatti, M. Krieger & A. Rigotti: Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 23,1732-1738 (2003)
164. A. Rigotti, B. Trigatti, J. Babitt, M. Penman, S. Xu & M. Krieger: Scavenger receptor BI-a cell surface receptor for high density lipoprotein. Curr Opin Lipidol 8,181-188 (1997)
165. G. Cao, C.K. Garcia, K.L. Wyne, R.A. Schultz, K.L. Parker & H.H. Hobbs: Structure and localization of the human gene encoding SR-BI/CLA-1. Evidence for transcriptional control by steroidogenic factor 1. J Biol Chem 272,33068-33076 (1997)
166. N. Wang, W. Weng, J.L. Breslow & A.R. Tall: Scavenger receptor BI (SR-BI) is up-regulated in adrenal gland in apolipoprotein A-I and hepatic lipase knock-out mice as a response to depletion of cholesterol stores. In vivo evidence that SR-BI is a functional high density lipoprotein receptor under feedback control. J Biol Chem 271,21001-21004 (1996)
167. M. Krieger: Charting the fate of the "good cholesterol": identification and characterization of the high-density lipoprotein receptor SR-BI. Annu Rev Biochem 68,523-558 (1999)
168. B. Trigatti, S. Covey & A. Rizvi: Scavenger receptor class B type I in high-density lipoprotein metabolism, atherosclerosis and heart disease: lessons from gene-targeted mice. Biochem Soc Trans 32,116-120 (2004)
169. M. Van Eck, M. Pennings, M. Hoekstra, R. Out & T.J. Van Berkel: Scavenger receptor BI and ATP-binding cassette transporter A1 in reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol 16,307-315 (2005)
170. M.L. Varban, F. Rinninger, N. Wang, V. Fairchild-Huntress, J.H. Dunmore, Q. Fang, M.L. Gosselin, K.L. Dixon, J.D. Deeds, S.L. Acton, A.R. Tall & D. Huszar: Targeted mutation reveals a central role for SR-BI in hepatic selective uptake of high density lipoprotein cholesterol. Proc Natl Acad Sci U S A 95,4619-4624 (1998)
171. A. Rigotti, B.L. Trigatti, M. Penman, H. Rayburn, J. Herz & M. Krieger: A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci U S A 94,12610-12615 (1997)
172. B. Trigatti, H. Rayburn, M. Vinals, A. Braun, H. Miettinen, M. Penman, M. Hertz, M. Schrenzel, L. Amigo, A. Rigotti & M. Krieger: Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc Natl Acad Sci U S A 96,9322-9327 (1999)
173. D.Q. Wang & M.C. Carey: Susceptibility to murine cholesterol gallstone formation is not affected by partial disruption of the HDL receptor SR-BI. Biochim Biophys Acta 1583,141-150 (2002)
174. P. Mardones, V. Quinones, L. Amigo, M. Moreno, J.F. Miquel, M. Schwarz, H.E. Miettinen, B. Trigatti, M. Krieger, S. VanPatten, D.E. Cohen & A. Rigotti: Hepatic cholesterol and bile acid metabolism and intestinal cholesterol absorption in scavenger receptor class B type I-deficient mice. J Lipid Res 42,170-180 (2001)
175. N. Wang, T. Arai, Y. Ji, F. Rinninger & A.R. Tall: Liver-specific overexpression of scavenger receptor BI decreases levels of very low density lipoprotein ApoB, low density lipoprotein ApoB, and high density lipoprotein in transgenic mice. J Biol Chem 273,32920-32926 (1998)
176. K.F. Kozarsky, M.H. Donahee, A. Rigotti, S.N. Iqbal, E.R. Edelman & M. Krieger: Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature 387,414-417 (1997)
177. Y. Ueda, L. Royer, E. Gong, J. Zhang, P.N. Cooper, O. Francone & E.M. Rubin: Lower plasma levels and accelerated clearance of high density lipoprotein (HDL) and non-HDL cholesterol in scavenger receptor class B type I transgenic mice. J Biol Chem 274,7165-7171 (1999)
178. Y. Ji, N. Wang, R. Ramakrishnan, E. Sehayek, D. Huszar, J.L. Breslow & A.R. Tall: Hepatic scavenger receptor BI promotes rapid clearance of high density lipoprotein free cholesterol and its transport into bile. J Biol Chem 274,33398-33402 (1999)
179. E. Sehayek, J.G. Ono, S. Shefer, L.B. Nguyen, N. Wang, A.K. Batta, G. Salen, J.D. Smith, A.R. Tall & J.L. Breslow: Biliary cholesterol excretion: a novel mechanism that regulates dietary cholesterol absorption. Proc Natl Acad Sci U S A 95,10194-10199 (1998)
180. Y. Ueda, E. Gong, L. Royer, P.N. Cooper, O.L. Francone & E.M. Rubin: Relationship between expression levels and atherogenesis in scavenger receptor class B, type I transgenics. J Biol Chem 275,20368-20373 (2000)
181. A. Rigotti, H.E. Miettinen & M. Krieger: The role of the high-density lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues. Endocr Rev 24,357-387 (2003)
182. A. Braun, B.L. Trigatti, M.J. Post, K. Sato, M. Simons, J.M. Edelberg, R.D. Rosenberg, M. Schrenzel & M. Krieger: Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Circ Res 90,270-276 (2002)
183. T. Arai, N. Wang, M. Bezouevski, C. Welch & A.R. Tall: Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene. J Biol Chem 274,2366-2371 (1999)
184. P.O. Yancey, M. de la Llera-Moya, S. Swarnakar, P. Monzo, S.M. Klein, M.A. Connelly, W.J. Johnson, D.L. Williams & G.H. Rothblat: High density lipoprotein phospholipid composition is a major determinant of the bidirectional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J Biol Chem 275,36596-36604 (2000)
185. S.D. Covey, M. Krieger, W. Wang, M. Penman & B.L. Trigatti: Scavenger receptor class B type I-mediated protection against atherosclerosis in LDL receptor-negative mice involves its expression in bone marrow-derived cells. Arterioscler Thromb Vasc Biol 23,1589-1594 (2003)
186. R. Out, J.K. Kruijt, P.C. Rensen, R.B. Hildebrand, P. de Vos, M. Van Eck & T.J. Van Berkel: Scavenger receptor BI plays a role in facilitating chylomicron metabolism. J Biol Chem 279,18401-18406 (2004)
187. R. Out, M. Hoekstra, S.C. de Jager, P. de Vos, D.R. van der Westhuyzen, N.R. Webb, M. Van Eck, E.A. Biessen & T.J. Van Berkel: Adenovirus-mediated hepatic overexpression of scavenger receptor class B type I accelerates chylomicron metabolism in C57BL/6J mice. J Lipid Res 46,1172-1181 (2005)
188. L. Cai, M.C. de Beer, F.C. de Beer & D.R. van der Westhuyzen: Serum amyloid A is a ligand for scavenger receptor class B type I and inhibits high density lipoprotein binding and selective lipid uptake. J Biol Chem 280,2954-2961 (2005)
189. M. Navab, G.M. Ananthramaiah, S.T. Reddy, B.J. Van Lenten, B.J. Ansell, G.C. Fonarow, K. Vahabzadeh, S. Hama, G. Hough, N. Kamranpour, J.A. Berliner, A.J. Lusis & A.M. Fogelman: The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 45,993-1007 (2004)
190. T. Cyrus, J.L. Witztum, D.J. Rader, R. Tangirala, S. Fazio, M.F. Linton & C.D. Funk: Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest 103,1597-1604 (1999)
191. T. Cyrus, D. Pratico, L. Zhao, J.L. Witztum, D.J. Rader, J. Rokach, G.A. FitzGerald & C.D. Funk: Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice. Circulation 103,2277-2282 (2001)
192. J. George, A. Afek, A. Shaish, H. Levkovitz, N. Bloom, T. Cyrus, L. Zhao, C.D. Funk, E. Sigal & D. Harats: 12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice. Circulation 104,1646-1650 (2001)
193. D. Harats, A. Shaish, J. George, M. Mulleins, H. Kurihara, H. Levkovitz & E. Sigal: Overexpression of 15-lipoxygenase in vascular endothelium accelerates early atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 20,2100-2105 (2000)
194. K.B. Reilly, S. Srinivasan, M.E. Hatley, M.K. Patricia, J. Lannigan, D.T. Bolick, G. Vandenhoff, H. Pei, R. Natarajan, J.L. Nadler & C.C. Hedrick: 12/15-Lipoxygenase activity mediates inflammatory monocyte/endothelial interactions and atherosclerosis in vivo. J Biol Chem 279,9440-9450 (2004)
195. B. Garner, A.R. Waldeck, P.K. Witting, K.A. Rye & R. Stocker: Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J Biol Chem 273,6088-6095 (1998)
196. A.D. Watson, J.A. Berliner, S.Y. Hama, B.N. La Du, K.F. Faull, A.M. Fogelman & M. Navab: Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96,2882-2891 (1995)
197. M.I. Mackness, S. Arrol, C. Abbott & P.N. Durrington: Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104,129-135 (1993)
198. M. Aviram, M. Rosenblat, C.L. Bisgaier, R.S. Newton, S.L. Primo-Parmo & B.N. La Du: Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 101,1581-1590 (1998)
199. D.I. Draganov, P.L. Stetson, C.E. Watson, S.S. Billecke & B.N. La Du: Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 275,33435-33442 (2000)
200. S.T. Reddy, D.J. Wadleigh, V. Grijalva, C. Ng, S. Hama, A. Gangopadhyay, D.M. Shih, A.J. Lusis, M. Navab & A.M. Fogelman: Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol 21,542-547 (2001)
201. A.D. Watson, M. Navab, S.Y. Hama, A. Sevanian, S.M. Prescott, D.M. Stafforini, T.M. McIntyre, B.N. Du, A.M. Fogelman & J.A. Berliner: Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 95,774-782 (1995)
202. M.C. Vohl, T.A. Neville, R. Kumarathasan, S. Braschi & D.L. Sparks: A novel lecithin-cholesterol acyltransferase antioxidant activity prevents the formation of oxidized lipids during lipoprotein oxidation. Biochemistry 38,5976-5981 (1999)
203. T.M. Forte, G. Subbanagounder, J.A. Berliner, P.J. Blanche, A.O. Clermont, Z. Jia, M.N. Oda, R.M. Krauss & J.K. Bielicki: Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice. J Lipid Res 43,477-485 (2002)
204. M. Navab, S.Y. Hama, C.J. Cooke, G.M. Anantharamaiah, M. Chaddha, L. Jin, G. Subbanagounder, K.F. Faull, S.T. Reddy, N.E. Miller & A.M. Fogelman: Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 41,1481-1494 (2000)
205. V.W. Bowry, K.K. Stanley & R. Stocker: High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci U S A 89,10316-10320 (1992)
206. J. Christison, A. Karjalainen, J. Brauman, F. Bygrave & R. Stocker: Rapid reduction and removal of HDL- but not LDL-associated cholesteryl ester hydroperoxides by rat liver perfused in situ. Biochem J 314 (Pt 3),739-742 (1996)
207. W. Sattler & R. Stocker: Greater selective uptake by Hep G2 cells of high-density lipoprotein cholesteryl ester hydroperoxides than of unoxidized cholesteryl esters. Biochem J 294 (Pt 3),771-778 (1993)
208. T. Hayek, J. Oiknine, G. Dankner, J.G. Brook & M. Aviram: HDL apolipoprotein A-I attenuates oxidative modification of low density lipoprotein: studies in transgenic mice. Eur J Clin Chem Clin Biochem 33,721-725 (1995)
209. V. Konig, U. Hopf, B. Moller, H. Lobeck, G. Assmann, M. Freudenberg & C. Galanos: The significance of high-density lipoproteins (HDL) in the clearance of intravenously administered bacterial lipopolysaccharides (LPS) in mice. Hepatogastroenterology 35,111-115 (1988)
210. A. Wu, C.J. Hinds & C. Thiemermann: High-density lipoproteins in sepsis and septic shock: metabolism, actions, and therapeutic applications. Shock 21,210-221 (2004)
211. M. Navab, G.M. Anantnaramaiah, S. Hama, G. Hough, S.T. Reddy, J.S. Frank, D.W. Gaiber, S. Handattu & A.M. Fogelman: D-4F and Statins Synergize to Render HDL Anti-inflammatory in Mice and Monkeys and Cause Lesion Regression in Old Apolipoprotein E Null Mice. Arterioscler Thromb Vasc Biol (2005)
212. H. Gupta, L. Dai, G. Datta, D.W. Garber, H. Grenett, Y. Li, V. Mishra, M.N. Palgunachari, S. Handattu, S.H. Gianturco, W.A. Bradley, G.M. Anantharamaiah & C.R. White: Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide. Circ Res 97,236-243 (2005)
213. V.G. Cabana, C.A. Reardon, N. Feng, S. Neath, J. Lukens & G.S. Getz: Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response. J Lipid Res 44,780-792 (2003)
214. B. De Geest, D. Stengel, M. Landeloos, M. Lox, L. Le Gat, D. Collen, P. Holvoet & E. Ninio: Effect of overexpression of human apo A-I in C57BL/6 and C57BL/6 apo E-deficient mice on 2 lipoprotein-associated enzymes, platelet-activating factor acetylhydrolase and paraoxonase. Comparison of adenovirus-mediated human apo A-I gene transfer and human apo A-I transgenesis. Arterioscler Thromb Vasc Biol 20,E68-75 (2000)
215. R.C. Sorenson, C.L. Bisgaier, M. Aviram, C. Hsu, S. Billecke & B.N. La Du: Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol 19,2214-2225 (1999)
216. H.M. Dansky, S.A. Charlton, C.B. Barlow, M. Tamminen, J.D. Smith, J.S. Frank & J.L. Breslow: Apo A-I inhibits foam cell formation in Apo E-deficient mice after monocyte adherence to endothelium. J Clin Invest 104,31-39 (1999)
217. G.D. Norata, E. Callegari, M. Marchesi, G. Chiesa, P. Eriksson & A.L. Catapano: High-density lipoproteins induce transforming growth factor-beta2 expression in endothelial cells. Circulation 111,2805-2811 (2005)
218. P. Holvoet, K. Peeters, S. Lund-Katz, A. Mertens, P. Verhamme, R. Quarck, D. Stengel, M. Lox, E. Deridder, H. Bernar, M. Nickel, G. Theilmeier, E. Ninio & M.C. Phillips: Arg123-Tyr166 domain of human ApoA-I is critical for HDL-mediated inhibition of macrophage homing and early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 21,1977-1983 (2001)
219. E. Boisfer, D. Stengel, D. Pastier, P.M. Laplaud, N. Dousset, E. Ninio & A.D. Kalopissis: Antioxidant properties of HDL in transgenic mice overexpressing human apolipoprotein A-II. J Lipid Res 43,732-741 (2002)
220. C.L. Kuo & B.N. La Du: Calcium binding by human and rabbit serum paraoxonases. Structural stability and enzymatic activity. Drug Metab Dispos 26,653-660 (1998)
221. M.I. Mackness, P.N. Durrington & B. Mackness: How high-density lipoprotein protects against the effects of lipid peroxidation. Curr Opin Lipidol 11,383-388 (2000)
222. L. Rodrigo, B. Mackness, P.N. Durrington, A. Hernandez & M.I. Mackness: Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem J 354,1-7 (2001)
223. C.J. Ng, D.M. Shih, S.Y. Hama, N. Villa, M. Navab & S.T. Reddy: The paraoxonase gene family and atherosclerosis. Free Radic Biol Med 38,153-163 (2005)
224. D.M. Shih, L. Gu, Y.R. Xia, M. Navab, W.F. Li, S. Hama, L.W. Castellani, C.E. Furlong, L.G. Costa, A.M. Fogelman & A.J. Lusis: Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394,284-287 (1998)
225. D.M. Shih, Y.R. Xia, X.P. Wang, E. Miller, L.W. Castellani, G. Subbanagounder, H. Cheroutre, K.F. Faull, J.A. Berliner, J.L. Witztum & A.J. Lusis: Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 275,17527-17535 (2000)
226. O. Rozenberg, M. Rosenblat, R. Coleman, D.M. Shih & M. Aviram: Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic Biol Med 34,774-784 (2003)
227. M.N. Oda, J.K. Bielicki, T.T. Ho, T. Berger, E.M. Rubin & T.M. Forte: Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins. Biochem Biophys Res Commun 290,921-927 (2002)
228. A. Tward, Y.R. Xia, X.P. Wang, Y.S. Shi, C. Park, L.W. Castellani, A.J. Lusis & D.M. Shih: Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 106,484-490 (2002)
229. O. Rozenberg, D.M. Shih & M. Aviram: Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis 181,9-18 (2005)
230. G. Theilmeier, B. De Geest, P.P. Van Veldhoven, D. Stengel, C. Michiels, M. Lox, M. Landeloos, M.J. Chapman, E. Ninio, D. Collen, B. Himpens & P. Holvoet: HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice. Faseb J 14,2032-2039 (2000)
231. R. Quarck, B. De Geest, D. Stengel, A. Mertens, M. Lox, G. Theilmeier, C. Michiels, M. Raes, H. Bult, D. Collen, P. Van Veldhoven, E. Ninio & P. Holvoet: Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 103,2495-2500 (2001)
232. H. Noto, M. Hara, K. Karasawa, O.N. Iso, H. Satoh, M. Togo, Y. Hashimoto, Y. Yamada, T. Kosaka, M. Kawamura, S. Kimura & K. Tsukamoto: Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress. Arterioscler Thromb Vasc Biol 23,829-835 (2003)
233. M. Hase, M. Tanaka, M. Yokota & Y. Yamada: Reduction in the extent of atherosclerosis in apolipoprotein E-deficient mice induced by electroporation-mediated transfer of the human plasma platelet-activating factor acetylhydrolase gene into skeletal muscle. Prostaglandins Other Lipid Mediat 70,107-118 (2002)
234. C.H. Chen: Platelet-activating factor acetylhydrolase: is it good or bad for you? Curr Opin Lipidol 15,337-341 (2004)
235. A. Zalewski & C. Macphee: Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 25,923-931 (2005)
236. V. Tsimihodimos, S.A. Karabina, A.P. Tambaki, E. Bairaktari, J.A. Goudevenos, M.J. Chapman, M. Elisaf & A.D. Tselepis: Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol 22,306-311 (2002)
237. V. Tsimihodimos, A Kakafika, A.P. Tambaki, E. Bairaktari, M.J. Chapman, M. Elisaf & AD. Tselepis: Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. J Lipid Res 44,927-934 (2003)
238. Y. Murakami, S. Kamiyama, Z.H. Howlader, T. Yamato, M. Komai & Y. Furukawa: Lecithin: cholesterol acyltransferase is insufficient to prevent oxidative modification of low-density lipoprotein. J Biochem (Tokyo) 131,17-19 (2002)
239. A. Mertens, P. Verhamme, J.K. Bielicki, M.C. Phillips, R. Quarck, W. Verreth, D. Stengel, E. Ninio, M. Navab, B. Mackness, M. Mackness & P. Holvoet: Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis. Circulation 107,1640-1646 (2003)
240. T.M. Forte, M.N. Oda, L. Knoff, B. Frei, J. Suh, J.A. Harmony, W.D. Stuart, E.M. Rubin & D.S. Ng: Targeted disruption of the murine lecithin:cholesterol acyltransferase gene is associated with reductions in plasma paraoxonase and platelet-activating factor acetylhydrolase activities but not in apolipoprotein J concentration. J Lipid Res 40,1276-1283 (1999)
241. B.P. Kennedy, P. Payette, J. Mudgett, P. Vadas, W. Pruzanski, M. Kwan, C. Tang, D.E. Rancourt & W.A. Cromlish: A natural disruption of the secretory group II phospholipase A2 gene in inbred mouse strains. J Biol Chem 270,22378-22385 (1995)
242. C.A Burton, S. Patel, S. Mundt, H. Hassing, D. Zhang, A. Hermanowski-Vosatka, S.D. Wright, Y.S. Chao, P.A. Detmers & C.P. Sparrow: Deficiency in sPLA(2) does not affect HDL levels or atherosclerosis in mice. Biochem Biophys Res Commun 294,88-94 (2002)
243. N. Leitinger, A.D. Watson, S.Y. Hama, B. Ivandic, J.H. Qiao, J. Huber, K.F. Faull, D.S. Grass, M. Navab, A.M. Fogelman, F.C. de Beer, A.J. Lusis & J.A. Berliner: Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids. Arterioscler Thromb Vasc Biol 19,1291-1298 (1999)
244. U.J. Tietge, D. Pratico, T. Ding, C.D. Funk, R.B. Hildebrand, T.J. Van Berkel & M. Van Eck: Macrophage-specific expression of type IIA secretory phospholipase A2 results in accelerated early atherogenesis by increasing oxidative stress in LDL-receptor deficient mice. J Lipid Res (2005)
245. M.A. Ostos, M. Conconi, L. Vergnes, N. Baroukh, J. Ribalta, J. Girona, J.M. Caillaud, A. Ochoa & M.M. Zakin: Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 21,1023-1028 (2001)
246. T. Vowinkel, M. Mori, C.F. Krieglstein, J. Russell, F. Saijo, S. Bharwani, R.H. Turnage, W.S. Davidson, P. Tso, D.N. Granger & T.J. Kalogeris: Apolipoprotein A-IV inhibits experimental colitis. J Clin Invest 114,260-269 (2004)
247. G.J. Kelso, W.D. Stuart, R.J. Richter, C.E. Furlong, T.C. Jordan-Starck & J.A. Harmony: Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry 33,832-839 (1994)
248. M.E. Rosenberg, R. Girton, D. Finkel, D. Chmielewski, A. Barrie, 3rd, D.P. Witte, G. Zhu, J.J. Bissler, J.A. Harmony & B.J. Aronow: Apolipoprotein J/clusterin prevents a progressive glomerulopathy of aging. Mol Cell Biol 22,1893-1902 (2002)
249. D. Yan, M. Navab, C. Bruce, A.M. Fogelman & X.C. Jiang: PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity. J Lipid Res 45,1852-1858 (2004)
250. X.P. Yang, D. Van, C. Qiao, R.J. Liu, J.G. Chen, J. Li, M. Schneider, L. Lagrost, X. Xiao & X.C. Jiang: Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression. Arterioscler Thromb Vasc Biol 23,1601-1607 (2003)
251. G. Assmann & J.R. Nofer: Atheroprotective effects of high-density lipoproteins. Annu Rev Med 54321-341 (2003)
252. P.J. Barter, S. Nicholls, K.A. Rye, G.M. Anantharamaiah, M. Navab & A.M. Fogelman: Antiinflammatory properties of HDL. Circ Res 95,764-772 (2004)
253. I.S. Yuhanna, Y. Zhu, B.E. Cox, L.D. Hahner, S. Osborne-Lawrence, P. Lu, Y.L. Marcel, R.G. Anderson, M.E. Mendelsohn, H.H. Hobbs & P.W. Shaul: High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med 7,853-857 (2001)
254. C. Mineo & P.W. Shaul: HDL stimulation of endothelial nitric oxide synthase: a novel mechanism of HDL action. Trends Cardiovasc Med 13,226-231 (2003)
255. C. Mineo, I.S. Yuhanna, M.J. Quon & P.W. Shaul: High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem 278,9142-9149 (2003)
256. J.R. Nofer, M. van der Giet, M. Tolle, I. Wolinska, K. von Wnuck Lipinski, H.A. Baba, U.J. Tietge, A. Godecke, I. Ishii, B. Kleuser, M. Schafers, M. Fobker, W. Zidek, G. Assmann, J. Chun & B. Levkau: HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 113,569-581 (2004)
257. P.W. Shaul & C. Mineo: HDL action on the vascular wall: is the answer NO? J Clin Invest 113,509-513 (2004)